



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

COVID-19 vaccination and changes in the menstrual cycle among vaccinated persons

Leslie V. Farland, Sc.D.,^{a,b,c} Sana M. Khan, M.P.H.,^a Alexandra Shilen, M.P.H.,^a Kelly M. Heslin, M.P.H.,^a Providence Ishimwe, M.P.H.,^a Alicia M. Allen, Ph.D.,^{a,d} Melissa M. Herbst-Kralovetz, Ph.D.,^{c,e,f} Nichole D. Mahnert, M.D.,^f Kristen Pogreba-Brown, Ph.D.,^a Kacey C. Ernst, Ph.D.,^a and Elizabeth T. Jacobs, Ph.D.^{a,c}

^a Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona;

^b Department of Obstetrics and Gynecology, College of Medicine-Tucson, University of Arizona; ^c University of Arizona Cancer Center, University of Arizona; ^d Department of Family and Community Medicine, College of Medicine-Tucson, University of Arizona; ^e Department of Basic Medical Sciences, College of Medicine-Phoenix, University of Arizona; and ^f Department of Obstetrics and Gynecology, College of Medicine-Phoenix, University of Arizona

Objective: To describe the characteristics of people who experience changes to their menstrual cycle after COVID-19 vaccination.

Design: Longitudinal study.

Patient(s): We recruited a volunteer sample with and without a history of SARS-CoV-2 infection who enrolled in the Arizona COVID-19 Cohort (CoVHORT) study and participated in a reproductive sub-cohort who were pre-menopausal, not pregnant, and had received a COVID-19 vaccine in 2021 (n = 545).

Exposure(s): Demographic and reproductive characteristics were collected via self-reports.

Main Outcome Measure(s): Information on self-reported changes in the menstrual cycle after COVID-19 vaccination was collected from May 2021 to December 2021. We looked at demographic and reproductive characteristics as predictors of menstrual cycle change.

Result(s): The majority of our vaccinated sample received the Pfizer-BioNTech vaccine (58%), and were 26–35 years old (51%), non-Hispanic (84%), and White (88%). Approximately 25% of vaccinated participants reported a change in their menstrual cycle after vaccination; the majority reported changes after their second dose (56%) as compared with their first (18%) and third (14%) doses. The most commonly reported changes were irregular menstruation (43%), increased premenstrual symptoms (34%), increased menstrual pain or cramps (30%), and abnormally heavy or prolonged bleeding (31%). High self-reported perceived stress levels compared with low perceived stress (OR, 2.22; 95% CI 1.12–4.37) and greater body mass index (OR, 1.04; 95% CI 1.00–1.07) were associated with greater odds of experiencing the menstrual cycle changes after the vaccination. Participants having a history of SARS-CoV-2 infection were less likely to report changes in their menstrual cycle after vaccination compared with the participants with no history of SARS-CoV-2 infection (OR, 0.58; 95% CI 0.32–1.04).

Conclusion(s): Among vaccinated participants, approximately 25% of them reported predominantly temporary changes in the menstrual cycle, however, we are unable to determine whether these changes are due to normal cycle variability. The COVID-19 vaccines are safe and effective for everyone, including pregnant people and people trying to conceive; hence, these findings should not discourage vaccination. (Fertil Steril® 2023;119:392–400. ©2022 by American Society for Reproductive Medicine.)

El resumen está disponible en Español al final del artículo.

Key Words: COVID-19 vaccination, menstrual cycle, SARS-CoV-2, menstrual regularity

In December 2020, the United States Food and Drug Administration (FDA) authorized the emergency

use of the Pfizer-BioNTech vaccine against SARS-CoV-2 infection and the associated disease state, COVID-19. Af-

ter this approval along with Moderna and Janssen vaccines, the United States has undertaken the largest and most comprehensive vaccination campaign in recent history. While the information on traditional adverse reactions from vaccination is required in clinical trials by the FDA and has been systematically collected on a national level by the Centers for Disease Control and Prevention, standardized collection of information on menstrual cycle health changes has been neglected in the current surveillance.

Received May 16, 2022; revised and accepted December 13, 2022; published online December 17, 2022.

L.V.F. has nothing to disclose. S.M. K. has nothing to disclose. A.S. has nothing to disclose. K.M.H. has nothing to disclose. P.I. has nothing to disclose. A.M.A. has nothing to disclose. M.M.H.-K. has nothing to disclose. N.D.M. has nothing to disclose. K.P.-B. has nothing to disclose. K.C.E. has nothing to disclose. E.T.J. has nothing to disclose.

Supported by a challenge grant from the University of Arizona and by the BIO-5 Institute at the University of Arizona.

Correspondence: Elizabeth T. Jacobs, Ph.D., University of Arizona, 1295 N Martin Ave, Drachman Hall A236, Tucson, Arizona (E-mail: jacobse@arizona.edu).

Fertility and Sterility® Vol. 119, No. 3, March 2023 0015-0282/\$36.00

Copyright ©2022 American Society for Reproductive Medicine, Published by Elsevier Inc.

<https://doi.org/10.1016/j.fertnstert.2022.12.023>

There is increasing evidence to suggest that SARS-CoV-2 infection as well as societal changes associated with the COVID-19 pandemic, may influence menstrual cycle health (1–6). Severe SARS-CoV-2 infection has been associated with adverse changes in ovarian function and menstruation, including decreased anti-mullerian hormone levels (1), as well as an increased prevalence of amenorrhea, menstrual volume changes, and dysmenorrhea among patients with COVID-19 (2). Other research focused on the societal impact of the COVID-19 pandemic and government-instituted lockdowns, observed that nearly half of the women surveyed reported changes to their menstrual cycle between March 2020 and September 2020 (3) which was attributable to stress. However, there has been limited published research on menstrual cycle health and COVID-19 vaccination (7), despite the biological plausibility of an association via immunomodulation of menstruation-associated hormones (8). The majority of the information on menstrual cycle changes after COVID-19 vaccination has come from media articles and anecdotal accounts having limited validity and may not be generalizable to all women considering vaccination (9). However, to date, there is a paucity of data regarding how long any potential changes to the menstrual cycle may persist after vaccination. Therefore, we utilized our ongoing Arizona COVID-19 Cohort Study (CoVHORT), to quantify the prevalence of menstrual changes after vaccination, the duration of change, and the associated risk factors among those vaccinated for COVID-19.


MATERIALS AND METHODS

In May 2020, the Arizona CoVHORT began recruiting participants for a prospective cohort study (10). The primary objective of this cohort was to better understand all COVID-19 risk factors, as well as the short-and long-term sequelae associated with infection through enrolling a longitudinal cohort

of individuals with and without a history of SARS-CoV-2 infection in Arizona state. In brief, SARS-CoV-2-positive individuals were recruited through case investigations and testing sites in collaboration with local health departments. Individuals without SARS-CoV-2 infection were recruited through a variety of sources including testing sites (those who tested negative), mailed postcards, flyers, and emails disseminated across the state. In May 2021, a reproductive health sub-study was launched which recruited CoVHORT study participants ($n = 2,367$) who were menstruating and aged 18–45 years. Enrollment in the reproductive sub-study was rolling and participants could enter the sub-cohort between May 2021 and December 2021 ($n = 703$). All participants were invited to complete a baseline (launched in May 2021), 3-month (launched in August 2021), and 6-month (launched in December 2021) questionnaire. While enrollment was active until December 2021, approximately 81% of our patients completed the baseline questionnaire in May 2021. For this analysis, we excluded participants who self-identified as pregnant, postmenopausal, perimenopausal, experienced hysterectomy or oophorectomy, or who did not receive 2 doses of the Pfizer-BioNTech or the Moderna vaccine or 1 dose of the Jansen vaccine, leaving a final sample of 545 participants (Fig. 1) who completed the baseline survey and were included in our analysis. The 3- and 6-month surveys were completed by 417 and 391 participants, respectively. We did not observe meaningful differences between the CoVHORT participants who were eligible, those enrolled in the reproductive sub-study, our analytic sample, and participants who completed the 3 and 6-month questionnaires (Supplemental Table 1, available online). The CoVHORT study and the reproductive sub-study were approved by the University of Arizona IRB (Protocol number: 2101406252).

On the baseline questionnaire of the reproductive sub-study, participants were asked detailed questions about their

FIGURE 1



Flow diagram of study participants.

Farland. COVID-19 vaccination and menstruation. *Fertil Steril* 2023.

TABLE 1

Descriptive characteristics of participants who had received the COVID-19 vaccine and reported changes in their menstrual cycles (n = 545)

	n (%)
Reported changes in the menstrual cycle after COVID-19 vaccination	135 (24.8)
When they first noticed changes	
After 1st dose	25 (18.5)
After 2nd dose	76 (56.3)
After 3rd dose	19 (14.1)
Unsure	15 (11.1)
Menstrual changes resolved ^a	
Yes, I am no longer experiencing changes	24 (17.8)
No, I am still experiencing changes	71 (52.6)
I don't know	28 (20.7)
Time until changes resolved (mo) ^b	
1	4 (16.7)
2	10 (41.7)
3	3 (12.5)
4	3 (12.5)
5	2 (8.3)
6	2 (8.3)
Specific changes in the menstrual cycle—at the first reported change in the cycle	
One or more missed menstrual periods	16 (11.9)
Infrequent menstruation (i.e., menstrual periods occurring at intervals >35 d)	14 (10.3)
Irregular menstruation (i.e., the number of days your menstrual period lasts or the time between each varies significantly)	58 (43.0)
Abnormal bleeding or spotting between normal menstrual periods	32 (23.7)
Abnormally heavy or prolonged bleeding (i.e., bleeding for longer than a wk, needing to use double the sanitary protection to control your menstrual flow)	42 (31.1)
Abnormally light bleeding	22 (16.3)
Increase in menstrual pain or cramps	41 (30.4)
Increase in premenstrual symptoms (i.e., greater than usual mood swings, feelings of anxiety/depression, tiredness, trouble sleeping, bloating/stomach pain, breast tenderness, changes in appetite or sex drive)	46 (34.1)
Survey where participant reported their first vaccination	
Baseline	135 (100)
3 mo	0 (0)
6 mo	0 (0)
Percent of participants that reported changes in their menstrual cycle by survey ^c	
Baseline	101 (74.8)
3 mo	22 (16.3)
6 mo	12 (8.9)

Farland. COVID-19 vaccination and menstruation. *Fertil Steril* 2023.

TABLE 1

Continued.

	n (%)
	Mean (SD)
	Median [min-max]
Days from the first vaccine dose to the completion of the first survey where they reported a change in their menstrual cycle	137 (79)
	118.5 [29-380]
Days from the second vaccine dose to the completion of the first survey where they reported a change	112 (79)
	91 [6-359]
Days from the first vaccine dose to completion of the first survey where they reported resolution to menstrual changes	166.8 (69.5)
	152.5 [61-352]
Days from the second vaccine dose to completion of the first survey where they reported resolution to menstrual changes	141.9 (69.8)
	125.5 [39-331]

^a Missing data for changes resolved (n = 12, 8.9%) at the last reported survey.

^b Among those who reported changes had resolved (n = 24); based on the write-in question: "Approximately how many months after vaccination did these changes resolve?"

^c 545 participants completed the baseline questionnaire, 417 completed the 3-month questionnaire, 391 completed the 6-month questionnaire.

Farland. COVID-19 vaccination and menstruation. *Fertil Steril* 2023.

demographics, reproductive and overall health history, self-reported stress using the perceived stress scale (PSS-10) (4), COVID-19 vaccination status, and changes to the menstrual cycle after vaccination. Changes to the menstrual cycle after vaccination were also asked on the 3-month and 6-month surveys along with information on pre- and postvaccination menstrual cycle characteristics such as menstrual cycle length and heaviness of menstrual flow. Specifically, participants were asked, "Since receiving the COVID-19 vaccine, have you noticed a change in your menstrual cycle?" If participants indicated "yes," they could choose one or more of the after responses: missed periods, infrequent menstruation (i.e. menstrual periods occurring at intervals >35 days), irregular menstruation (i.e. the number of days your menstrual period lasts or the time between each varies significantly), abnormal bleeding or spotting between the menstrual periods, abnormally light bleeding, abnormally heavy or prolonged bleeding (i.e. bleeding for longer than a week, need to use double sanitary protection to control the menstrual flow), increased menstrual pain or cramps, and increase in premenstrual symptoms (i.e. greater than usual mood swings, feelings of anxiety/depression, tiredness, trouble sleeping, bloating/stomach pain, breast tenderness, changes in appetite or sex drive). Participants were also asked when they first noticed menstrual changes (after dose 1, dose 2, and dose 3 (added to the 6-month questionnaire in December 2021), or unsure), whether the menstrual changes had resolved, and when they had resolved (approximately how many months after vaccination did these changes resolve). The survey item employed to address resolution was as follows: "Approximately how many months after vaccination did these changes resolve?". Information on self-reported history of polymerase chain reaction and antigen-confirmed SARS-CoV-2 status and body

mass index (BMI; kg/m²) were obtained through linkages with the parent CoVHORT study.

In this analysis, we quantified the prevalence of self-reported changes to the menstrual cycle among women who were vaccinated against SARS-CoV-2, the timing of onset and resolution, as well as type of menstrual changes. We also compared the demographic and reproductive characteristics of those participants who reported and did not report changes in their menstrual cycle after COVID-19 vaccination. We employed logistic regression analyses to calculate odds ratios and 95% confidence intervals of changes to the menstrual cycle for a variety of demographic and reproductive characteristics (Stata 17.0).

RESULTS

Figure 1 presents the study flow diagram for the reproductive sub-cohort. Information regarding the study was sent to 2,367 eligible participants in the CoVHORT. A total of 703 participants completed baseline surveys and enrolled in the reproductive sub-cohort; whereas 545 participants were eligible for our analytic sample. Three- and six-month surveys were completed by 417 and 391 women, respectively in our analytic sample. Among participants (n = 545), the majority (64.2%) reported tracking their menstrual periods using a phone application, calendar, or other devices. We observed that 24.8% of patients reported a change in their menstrual cycle after vaccination (Table 1). Among participants who reported changes to their menstrual cycle (n = 135), the majority (56.3%) of them reported these differences after their second dose of vaccine as compared with their first (18%) and third (14%) doses. Among participants who reported changes in their menstrual cycles, 17.8% of patients reported resolution of changes, with the majority (58%) resolving within 2 months of vaccination. Of the specific changes to the menstrual cycle, irregular menstruation, defined as an affirmative response to the query of whether the number of days the menstrual period lasted or the time between each varied significantly, was the most commonly reported change (43.0%), followed by increased premenstrual symptoms (34.1%), increased menstrual pain/cramps (30.4%), and abnormally heavy or prolonged bleeding (31.1%).

The majority of participants received the Pfizer-BioNTech vaccine (58%), were 26–35 years old (51%), non-Hispanic (84%), and White (88%) (Table 2). We observed no statistically significant differences in age, race/ethnicity, history of other chronic conditions, gravidity, subfertility, and age at first menses among vaccinated participants who did and did not report changes to their menstrual cycle after vaccination. A greater BMI was associated with greater odds of experiencing changes to the menstrual cycle (OR, 1.04; 95% CI, 1.00–1.07). Compared with the participants who reported low perceived stress at baseline, participants who reported high perceived stress had greater odds of reporting changes to their menstrual cycle (OR, 2.22; 95% CI, 1.12–4.37). Participants having a history of SARS-CoV-2 infection were less likely to report changes to their menstrual cycle after vaccination compared with the participants with no history of SARS-CoV-2 infection (OR, 0.58; 95% CI, 0.32–1.04). Participants who reported

using any hormonal medication had 27% lower odds of reporting menstrual cycle changes (OR, 0.73; 95% CI, 0.49–1.08).

Among participants who reported ≥ 1 missed menstrual period on the baseline survey, 50% reported having missed 1 menstrual period, 14% reported missing 2, 14% missing 3, and 21% reported missing 4 menstrual periods on an average of 172 days (SD = 36) from the first vaccine. Among participants who reported infrequent or irregular menstruation after the vaccination, before the COVID-19 vaccine, they reported their cycles were an average of 27 days (SD = 6.1; median = 28); after the COVID-19 vaccine, when they noticed changes, their cycles were on average of 29 days (SD = 14; median = 31). Among participants who reported changes in bleeding heaviness (lighter or heavier), on average before vaccination within 4 hours, 11% reported experiencing spotting, 37% had experienced light bleeding, 41% had experienced moderate bleeding, and 11% had experienced heavy bleeding. After vaccination, on average within 4 hours, 15% reported experiencing spotting, 26% experienced light bleeding, 48% experienced moderate bleeding, and 11% experienced heavy bleeding. Among those who reported changes in premenstrual symptoms after vaccination, the most common symptoms reported to increase were tiredness (50%) and mood swings (43.5%).

DISCUSSION

Overall, we observed that approximately 25% of the participants reported changes in the menstrual cycle after COVID-19 vaccination, with the most common changes related to menstrual timing, premenstrual symptoms, pain symptoms, and abnormally heavy or prolonged bleeding. Compared with those who did not report changes to their menstrual cycle after vaccination, those who did experience variation had higher stress levels and greater BMI at baseline and were also less likely to have had prior SARS-CoV-2 infection, suggesting that these variables may also be associated with postvaccination menstrual cycle changes, which requires further investigation.

There are several hypothesized mechanisms through which vaccinations may influence menstrual cycles. Changes in the menstrual cycle may be caused by several factors including an acute-phase immune response, inflammation, endogenous hormone levels, and/or immune cells in the endometrium. Moreover, prior research has suggested that some people may experience short-term changes to the menstrual cycle after other vaccinations (11, 12). Indeed, data collected from New York Presbyterian Hospital in 1911 reported anecdotal accounts of changes to the menstrual cycle after typhoid vaccination (12), and more recently, menstrual irregularities have been reported to the FDA's Vaccine Adverse Events Reporting System after HPV vaccination (11). However, information on menstrual cycle health is not routinely collected in current vaccine trial documentation or surveillance. Previous research on menstrual cycle changes after COVID-19 vaccination among individuals using the digital application "Natural Cycles" (7), observed that compared with those who were unvaccinated, vaccinated individuals

TABLE 2

Demographic and reproductive characteristics among participants who received the COVID-19 vaccine were stratified by whether they experienced changes to their menstrual cycle after vaccination

Characteristics	People who reported changes in their menstrual cycle after vaccination (n = 135; 24.8%)	People who did not report a change to their menstrual cycle after vaccination (n = 410; 75.2%)	Odds of reporting menstrual changes after vaccination (95% CI)
Age (y), mean (SD)	32.5 (6.4)	32.3 (6.6)	1.00 (0.97–1.03)
Age(y); n (%)			
18–25	21 (15.6)	70 (17.0)	1.00 (Referent)
26–30	31 (23.0)	94 (22.9)	1.10 (0.58–2.07)
31–35	40 (29.6)	111 (27.1)	1.20 (0.65–2.20)
36–40	26 (19.3)	83 (20.2)	1.04 (0.54–2.01)
41–45	17 (12.6)	52 (12.7)	1.09 (0.52–2.26)
Vaccine type, n (%)			
Pfizer-BioNTech	85 (63.0)	229 (55.8)	1.00 (Referent)
Moderna	45 (33.3)	171 (41.7)	0.71 (0.47–1.07)
Janssen	5 (3.7)	10 (2.4)	1.34 (0.45–4.05)
Race, n (%)			
White	111 (87.4)	321 (87.5)	1.00 (Referent)
Black or African American	4 (3.2)	6 (1.6)	1.93 (0.53–6.96)
Asian	3 (2.4)	19 (5.2)	0.46 (0.13–1.58)
Mixed Race	9 (7.0)	21 (5.7)	1.24 (0.55–2.79)
Ethnicity, n (%)			
Non-Hispanic	108 (85.7)	309 (83.7)	1.00 (Referent)
Hispanic	18 (14.3)	60 (16.3)	0.86 (0.49–1.52)
BMI (kg/m ²), mean (SD)	27.5 (7.3)	26.0 (6.0)	1.04 (1.00–1.07)
BMI (kg/m ²), n (%)			
<18.5	2 (1.6)	7 (1.9)	1.02 (0.21–5.09)
18.5–24.9	55 (43.3)	198 (53.7)	1.00 (Referent)
25.0–29.9	37 (29.1)	86 (23.2)	1.55 (0.95–2.52)
30.0–39.9	26 (20.5)	64 (17.3)	1.46 (0.85–2.52)
≥40.0	7 (5.5)	14 (3.8)	1.80 (0.69–4.68)
History of SARS-CoV-2 infection ^a , n (%)	15 (11.1)	73 (17.8)	0.58 (0.32–1.04)
Perceived stress score ^b , mean, (SD)	18.8 (7.2)	17.3 (6.9)	1.03 (1.00–1.06)
Low stress	30 (22.2)	133 (32.4)	1.00 (Referent)
Moderate stress	86 (63.7)	239 (58.3)	1.60 (1.00–2.54)
High stress	19 (14.1)	38 (9.3)	2.22 (1.12–4.37)
History of other chronic conditions, n (%)			
Endometriosis	4 (3.0)	21 (5.1)	0.57 (0.19–1.68)
Polycystic ovary syndrome	12 (8.9)	31 (7.6)	1.19 (0.59–2.39)
Uterine fibroids	5 (3.7)	9 (2.2)	1.71 (0.56–5.20)
Diabetes (TI or TII)	3 (2.2)	3 (0.7)	3.08 (0.61–15.46)
Hypertension	10 (7.4)	21 (5.1)	1.48 (0.68–3.23)
Any chronic condition	94 (69.6)	280 (68.3)	1.06 (0.70–1.62)
Reproductive history			
Gravidity, mean (SD)	0.9 (1.4)	0.9 (1.3)	1.00 (0.87–1.16)
History of subfertility ^c , n (%)	12 (8.9)	47 (11.5)	0.75 (0.39–1.46)
Specific infertility diagnosis, n (%)			
tubal factor infertility	0 (0)	4 (1.0)	-
Polycystic ovary syndrome	2 (1.5)	8 (2.0)	-
Endometriosis	1 (0.8)	6 (1.5)	-
Uterine factor infertility	0 (0)	1 (0.2)	-
Male/Partner factor	4 (3.0)	5 (1.2)	-
Unknown	4 (3.0)	18 (4.4)	-
Other	3 (0.7)	3 (2.2)	-
Age at menses, y; n (%)			
≤10	7 (5.2)	29 (7.2)	0.69 (0.28–1.71)
11	31 (23.1)	85 (21.0)	1.05 (0.61–1.81)
12	41 (30.6)	118 (29.2)	1.00 (Referent)
13	35 (26.1)	96 (23.8)	1.05 (0.62–1.77)
≥14	20 (14.9)	76 (18.8)	0.76 (0.41–1.39)
Currently on any hormonal medication, n (%)			

Farland. COVID-19 vaccination and menstruation. *Fertil Steril* 2023.

TABLE 2

Continued.

Characteristics	People who reported changes in their menstrual cycle after vaccination (n = 135; 24.8%)	People who did not report a change to their menstrual cycle after vaccination (n = 410; 75.2%)	Odds of reporting menstrual changes after vaccination (95% CI)
Any hormonal medication (OCP, Hormonal IUD, Implant, Shot, Other)	57 (42.2)	205 (50)	0.73 (0.49-1.08)
Oral contraceptives—combination pill or progestin	26 (19.3)	96 (23.4)	0.78 (0.48-1.27)
Hormonal IUD	23 (17.0)	96 (23.4)	0.67 (0.41-1.11)
Hormonal implant	7 (5.2)	12 (2.9)	-
Hormonal shot	-	1 (0.2)	-
Other hormonal medication	1 (0.7)	2 (0.5)	-
No hormonal medication use	78 (57.8)	205 (50.0)	1.00 (Referent)

IUD = intrauterine device. Prefer not to answer or missing: race (n = 45); ethnicity (n = 44); BMI (n = 49); history of subfertility (n = 1); age at first menstrual period (n = 7); missing first vaccination date (n = 32); missing second vaccination date (n = 33); time from last menstrual period to last change (n = 2); age at menses (n = 7);

^a Defined as polymerase chain reaction or antigen-confirmed positive COVID-19 test before second COVID-19 vaccination

^b Perceived stress was measured using the PSS-10

^c Subfertility was defined as a history of ≥ 6 months of trying to conceive without success

Farland. COVID-19 vaccination and menstruation. *Fertil Steril* 2023.

experienced a 0.6-day increase in their cycle after their first vaccine dose and a 0.8-day increase in their cycle after their second vaccine dose in adjusted models. Among individuals who received both vaccine doses within a single menstrual cycle, individuals experienced a 2.3-day increase in their menstrual cycle length compared with the unvaccinated individuals. Approximately, 10% of the participants experienced cycle length changes of ≥ 8 days, however this change attenuated after 2 postvaccine cycles. These findings are consistent with more recent findings among over 19,000 international users of the “Natural Cycles” application (13) and among nearly 4,000 participants in the Nurses’ Health Study 3 (14). In our study, we observed a two-day increase in menstrual cycle length among participants who reported infrequent or irregular menstruation after vaccination.

Societal stress related to the COVID-19 pandemic, independent of infection and vaccination, has also been hypothesized to modify the menstrual cycle (3, 4, 15). Results of an anonymous digital survey of over 1,000 reproductive-aged women recruited through social media in September 2020 observed that 46% of respondents reported a change in their menstrual cycle during the COVID-19 pandemic with 53% reporting worsening menstrual symptoms, 18% reporting new menorrhagia, and 30% reporting new dysmenorrhea (3). However, the majority of study participants were White (97%) and from Ireland and the United Kingdom (98%) limiting generalizability. Additionally, given recruitment through social media, participants who enrolled in the study may have been more likely to participate because of having experienced adverse menstrual or reproductive outcomes, thus potentially oversampling individuals who had menstrual cycle changes.

In our data, we are unable to disentangle whether reported changes in the menstrual cycle after COVID-19 vaccination can be attributed to other endogenous or exogenous factors. We observed that vaccinated participants who reported changes to their menstrual cycle had higher perceived

stress at the study baseline compared with participants who did not report changes. However, while stress is known to influence menstrual cycle regularity (16, 17), both groups had, on average, moderate stress. The instrument used to measure stress in our study was the PSS-10 which queries about stress in the previous 30 days. Hence, our measure of stress may be prone to reverse causation because participants completed the PSS-10 at baseline, on average 137 days after their first vaccine dose, and therefore, may not represent stress levels at the time of menstrual changes. We also observed that individuals with greater BMI may be more likely to experience menstrual cycle changes. Body size is associated with endogenous hormone levels and conditions that influence menstrual cycle regularity such as polycystic ovary syndrome (18, 19) and endometriosis (20). However, we did not observe clinically meaningful differences in polycystic ovary syndrome or endometriosis diagnoses between individuals who did and did not report menstrual changes. In addition, our data suggest that individuals who experienced changes in their menstrual cycle after vaccination were less likely to have had a history of SARS-CoV-2 infection (11%) compared with the individuals without any change in their menstrual cycle (18%). Prior research from our team has shown that acute infection may influence the menstrual cycle, as $\sim 16\%$ of individuals with SARS-CoV-2 infection reported changes to their menstrual cycles after their illness (2), with individuals who had more severe acute illness presentation and larger body size more likely to experience menstrual cycle changes. It is possible that because some individuals experienced changes after infection, they may underreport menstrual changes after vaccination.

Lastly, while the menstrual cycle is traditionally thought to be relatively stable among women 20–40 years old (21), it is normal for many women to experience variability in cycle length and symptoms (22–24). A recent analysis of >4 million menstrual cycles observed a median cycle length difference of 4.15 days (SD = 4.94) across cycles, with

approximately 8% of women consistently experiencing highly variable cycle lengths (>9 days) (23). Further, another study has demonstrated that 46% of individuals report a menstrual cycle range of ≥ 7 days, with 20% reporting a variation of ≥ 14 days (24). Therefore, random fluctuations in the menstrual cycle cannot be completely ruled out.

While this study has several strengths including being one of the first studies to quantify changes in the menstrual cycle after vaccination, we also recognize its limitations. The analysis utilizes self-reported, cross-sectional data, and some associations, such as with stress, may be due to reverse causation. Recruitment for the study came from the parent CoVHORT study and did not emphasize vaccination or menstrual cycle changes, however, women who have a history of reproductive health issues may be more likely to participate in a sub-study advertised as being focused on reproductive health. This study did not ask for menstrual cycle information among the unvaccinated and therefore we are unable to determine whether these changes would be expected among the unvaccinated. Participants who indicated resolution of changes to their menstrual cycle were asked to write “Approximately how many months after vaccination did these changes resolve?” Unfortunately, this question wording is not granular enough to allow for a detailed statistical analysis of time-to-symptom resolution, which should be incorporated into future research. Additionally, while our study could not account for effect modification by time, there may be differences observed by the calendar time of data collection given changes in vaccination rates and population-level awareness about menstrual changes after vaccination (25). Moreover, the phrasing of our survey about menstrual cycle changes was directly linked to vaccination status (“Since receiving the COVID-19 vaccine, have you noticed a change in your menstrual cycle?”) which may have caused participants to over-estimate the association between menstrual changes and vaccination status. Finally, bias with recall may have played a role in the findings of this study, as those who have been vaccinated may potentially be more likely to have noticed and reported changes to their menstrual cycle after media reporting before the survey and given the wording of the survey and as such, these results must be confirmed in larger studies.

Some individuals may notice changes to their menstrual cycle after COVID-19 vaccination. These findings should inform patient counseling regarding what to expect after COVID-19 vaccination. Menstrual changes occurred in 25% of our vaccinated patients. However, whether the COVID-19 vaccine directly caused these menstrual changes for all participants or whether these changes were part of normal fluctuations or caused by other factors warrants further investigation. The COVID-19 vaccines are safe and effective for everyone including pregnant people (26, 27) and people trying to conceive (28, 29). Future, prospective research is needed to replicate these findings. Moreover, additional research is needed to understand the potential mechanism of association and the duration of these changes.

In summary, among participants vaccinated for COVID-19, approximately 1 in 4 participants reported changes in

their menstrual cycle after vaccination, similar to reported changes after COVID-19 disease (2, 6), and may be due to normal menstrual cycle variability observed in the general population. These findings should not deter individuals from receiving the COVID-19 vaccine, as the vaccine is safe and effective for pregnant people (26, 27) and people trying to conceive (28–30). Additionally, vaccine safety and surveillance data should systematically collect information on the menstrual cycle and reproductive health. While we observed that COVID-19 vaccination was associated with menstrual cycle changes among some participants, these appear to be temporary. Moreover, we could not disentangle the influence of outside factors or normal variability. The risk of long-term health consequences after COVID-19 disease is substantial and may also include changes to the menstrual cycle; therefore, menstrual side effects should not prevent individuals from getting vaccinated.

REFERENCES

1. Ding T, Wang T, Zhang J, Cui P, Chen Z, Zhou S, et al. Analysis of ovarian injury associated with COVID-19 disease in reproductive-aged women in Wuhan, China: an observational study. *Front Med (Lausanne)* 2021;8:1–11.
2. Khan SM, Shilen A, Heslin KM, Ishimwe P, Allen AM, Jacobs ET, et al. SARS-CoV-2 infection and subsequent changes in the menstrual cycle among participants in the Arizona CoVHORT study. *Am J Obstet Gynecol* 2022;226:270–3.
3. Phelan N, Behan LA, Owens L. The impact of the COVID-19 pandemic on women's reproductive health. *Front Endocrinol* 2021;12:1–8.
4. Bruinvels G, Goldsmith E, Blagrove RC, Martin D, Shaw L, Piasecki J. How lifestyle changes within the COVID-19 global pandemic have affected the pattern and symptoms of the menstrual cycle. *Int J Environ Res Public Health* 2022;19:1–19.
5. Carli A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA* 2020;324:603–5.
6. Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. *Reprod Bio-med Online* 2021;42:260–7.
7. Edelman A, Boniface ER, Benhar E, Han L, Matteson KA, Favaro C, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort. *Obstet Gynecol* 2022;139:940–1.
8. Male V. Menstrual changes after Covid-19 vaccination. *BMJ* 2021;374:n2211.
9. Alice Lu-Culligan RHE. Can Covid shots affect periods? In: *New York Times*. New York; 2021:25.
10. Catalfamo CJ, Heslin KM, Shilen A, Khan SM, Hunsaker JR, Austhof E, et al. Design of the Arizona CoVHORT: a population-based COVID-19 cohort. *Front Public Health* 2021;9:1–11.
11. Gong L, Ji HH, Tang XW, Pan LY, Chen X, Jia YT. Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of vaccine adverse event reporting system. *Sci Rep* 2020;10:1–8.
12. Lamb AR. Experiences with prophylactic typhoid vaccination: its effect on menstruation. *Archives of Internal Medicine* 1913;XII:565–77.
13. Edelman A, Boniface ER, Male V, Cameron ST, Benhar E, Han L, et al. Association between menstrual cycle length and Covid-19 vaccination: global, retrospective cohort study of prospectively collected data. *BMJ Medicine* 2022;1:1–21.
14. Wang S, Mortazavi J, Hart JE, Hankins JA, Katuska LM, Farland LV, et al. A prospective study of the association between SARS-CoV-2 infection and COVID-19 vaccination with changes in usual menstrual cycle characteristics. *Am J Obstet Gynecol* 2022;227:739:e1–e11.
15. Demir O, Sal H, Comba C. Triangle of COVID, anxiety and menstrual cycle. *J Obstet Gynaecol* 2021;41:1257–61.

16. Critchley HOD, Babayev E, Bulun SE, Clark S, Garcia-Grau I, Gregersen PK, et al. Menstruation: science and society. *Am J Obstet Gynecol* 2020;223:624–64.
17. Nagma S, Kapoor G, Bharti R, Batra A, Batra A, Aggarwal A, et al. To evaluate the effect of perceived stress on menstrual function. *J Clin Diagn Res* 2015;9:Qc01–3.
18. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2013;98:4565–92.
19. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. *Nat Rev Endocrinol* 2011;7:219–31.
20. Farland LV, Harris HR. Long-term health consequences of endometriosis—pathways and mediation by treatment. *Curr Obstet Gynecol Rep* 2020;9:79–88.
21. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. *International journal of fertility* 1967;12:77–126.
22. Fehring RJ, Schneider M, Raviele K. Variability in the phases of the menstrual cycle. *J Obstet Gynecol Neonatal Nurs* 2006;35:376–84.
23. Li K, Urteaga I, Wiggins CH, Druet A, Shea A, Vitzthum VJ, et al. Characterizing physiological and symptomatic variation in menstrual cycles using self-tracked mobile-health data. *NPJ Digit Med* 2020;3:1–13.
24. Creinin MD, Keverline S, Meyn LA. How regular is regular? An analysis of menstrual cycle regularity. *Contraception* 2004;70:289–92.
25. Fell DB, Dimitris MC, Hutcheon JA, Ortiz JR, Platt RW, Regan AK, et al. Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy. *Vaccine* 2021;39:1882–6.
26. Razzaghi H, Meghani M, Pingali C, Crane B, Naleway A, Weintraub E, et al. COVID-19 vaccination coverage among pregnant women during pregnancy-eight integrated health care organizations, United States, December 14, 2020–May 8, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:895–9.
27. Joseph NT, Metz TD. Coronavirus disease 2019 (COVID-19) and pregnancy outcomes: state of the science. *Obstet Gynecol* 2021;138:539–41.
28. Morris RS. SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility. *F S Rep* 2021;2:253–5.
29. Orvieto R, Noach-Hirsh M, Segev-Zahav A, Haas J, Nahum R, Aizer A. Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle? *Reprod Biol Endocrinol* 2021;19:69.
30. Wesselink AK, Hatch EE, Rothman KJ, Wang TR, Willis MD, Yland J, et al. A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility. *Am J Epidemiol* 2022;191:1383–95.

Vacunación COVID-19 y cambios en el ciclo menstrual entre personas vacunadas.

Objetivo: Describir las características de la gente que experimenta cambios en su ciclo menstrual después de la vacunación COVID-19.

Diseño: Estudio longitudinal.

Paciente (s): Reclutamos una muestra voluntaria con y sin historia de infección de SARS-CoV-2 que se inscribió en el estudio de Cohorte COVID-19 de Arizona y participó en un sub-cohorte reproductivo que eran pre-menopáusicas, no embarazadas y habían recibido una vacuna COVID-19 en 2021 (n=545).

Intervención (es): Características demográficas y reproductivas fueron recolectadas via autoevaluación.

Principal (es) Medida (s) de Resultado (s): Información en la autoevaluación de cambios en el ciclo menstrual después de vacunación COVID-19 fue recolectada desde Mayo 2021 a Diciembre 2021. Buscamos características demográficas y reproductivas como predictores de cambios en el ciclo menstrual.

Resultado (s): La mayoría de nuestra muestra vacunada recibió la vacuna Pfizer-BioNTech (58%), y tenían 26-35 años (51%), no hispanas (84%), y blancas (88%). Aproximadamente 25% de las participantes vacunadas informaron un cambio en su ciclo menstrual después de la vacunación; la mayoría informó cambios después de la segunda dosis (56%) en comparación con la primera (18%) y la tercera (14%) dosis. Los cambios más comunes informados fueron menstruaciones irregulares (43%), aumento de síntomas premenstruales (34%), aumento de dolor menstrual o calambres (30%), y sangrado anormal abundante y prolongado (31%). Altos niveles de estrés se percibieron en las autoevaluaciones comparados con bajos niveles de estrés percibidos (OR, 2.22; 95% CI 1.12-4.37) y un mayor índice de masa corporal (OR, 1.04; 95% CI 1.00-1.07) fue asociado a mayor probabilidad de experimentar cambios en el ciclo menstrual después de la vacunación. Las participantes que tenían una historia de infección SARS-CoV-2 fueron menos propensas a informar cambios en su ciclo menstrual después de la vacunación comparadas con las participantes sin historia de infección SARS-CoV-2 (OR, 0.58; 95% CI 0.32-1.04).

Conclusión (es): Entre las participantes vacunadas, aproximadamente el 25% informó predominantemente cambios temporales en el ciclo menstrual, sin embargo, somos incapaces de determinar si estos cambios se deben a la variabilidad normal del ciclo. Las vacunas COVID-19 son seguras y efectivas para todos, incluyendo gente embarazada y gente tratando de concebir; por tanto, estos hallazgos no deben desalentar la vacunación.